SAGE Therapeutics (SAGE) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a sell rating to a hold rating in a research report report published on Wednesday.

A number of other brokerages also recently weighed in on SAGE. JPMorgan Chase & Co. reaffirmed a buy rating on shares of SAGE Therapeutics in a research note on Wednesday, January 10th. Stifel Nicolaus reissued a buy rating and set a $198.00 price target on shares of SAGE Therapeutics in a research note on Friday, December 8th. Cowen reissued a buy rating on shares of SAGE Therapeutics in a research note on Monday, December 11th. Morgan Stanley assumed coverage on shares of SAGE Therapeutics in a research note on Monday, February 26th. They set an overweight rating and a $225.00 price target on the stock. Finally, SunTrust Banks lifted their price target on shares of SAGE Therapeutics to $203.00 and gave the stock a buy rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $176.47.

How to Become a New Pot Stock Millionaire

Shares of SAGE Therapeutics (NASDAQ:SAGE) traded up $8.28 on Wednesday, reaching $177.75. 480,272 shares of the company were exchanged, compared to its average volume of 715,218. The stock has a market capitalization of $8,137.04, a P/E ratio of -24.96 and a beta of 3.07. SAGE Therapeutics has a 1-year low of $59.57 and a 1-year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.23. During the same quarter in the previous year, the company earned ($1.50) earnings per share. analysts expect that SAGE Therapeutics will post -8.2 EPS for the current fiscal year.

In other news, CEO Jeffrey M. Jonas sold 210,247 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $157.45, for a total value of $33,103,390.15. Following the transaction, the chief executive officer now owns 211,473 shares in the company, valued at $33,296,423.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Albert Robichaud sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the transaction, the insider now owns 152,759 shares in the company, valued at approximately $24,354,367.37. The disclosure for this sale can be found here. Insiders sold 372,386 shares of company stock worth $60,465,018 in the last 90 days. Company insiders own 6.10% of the company’s stock.

Several institutional investors have recently modified their holdings of SAGE. Oppenheimer Asset Management Inc. grew its holdings in shares of SAGE Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,565 shares during the last quarter. Bessemer Group Inc. bought a new position in shares of SAGE Therapeutics in the third quarter worth approximately $141,000. Fortaleza Asset Management Inc. bought a new position in shares of SAGE Therapeutics in the fourth quarter worth approximately $167,000. First Mercantile Trust Co. bought a new stake in SAGE Therapeutics in the fourth quarter valued at $169,000. Finally, Envestnet Asset Management Inc. boosted its holdings in SAGE Therapeutics by 70.7% in the third quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 1,204 shares in the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.

TRADEMARK VIOLATION WARNING: “SAGE Therapeutics (SAGE) Raised to “Hold” at BidaskClub” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/03/11/sage-therapeutics-sage-raised-to-hold-at-bidaskclub.html.

About SAGE Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply